Topical Interferon Gamma for Macular Edema Secondary to Uveitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

March 31, 2012

Conditions
Anterior UveitisUveitis
Interventions
DRUG

Interferon Gamma-1b

Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Eye Institute (NEI)

NIH

NCT01376362 - Topical Interferon Gamma for Macular Edema Secondary to Uveitis | Biotech Hunter | Biotech Hunter